Hainer, C., Mosienko, V., Koutsikou, S., Crook, J. J., Gloss, B., Kasparov, S., Lumb, B. M., & Alenina, N. (2015). Beyond Gene Inactivation: Evolution of Tools for Analysis of Serotonergic Circuitry. *ACS Chemical Neuroscience*, 6(7), 1116-1129.
<https://doi.org/10.1021/acschemneuro.5b00045>

Peer reviewed version

Link to published version (if available):
[10.1021/acschemneuro.5b00045](https://doi.org/10.1021/acschemneuro.5b00045)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via ACS at <http://pubs.acs.org/doi/abs/10.1021/acschemneuro.5b00045>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Beyond Gene Inactivation: Evolution of Tools for Analysis of Serotonergic Circuitry

Cornelia Hainer^{1,*}, Valentina Mosienko^{2,*,#}, Stella Koutsikou², Jonathan J. Crook², Bernd Gloss³, Sergey Kasparov², Bridget M. Lumb², Natalia Alenina^{1,4}

¹ Max-Delbrück-Center for Molecular Medicine (MDC), Berlin, Germany

² University of Bristol, Bristol, United Kingdom

³ National Institute of Environmental Health Science, Durham, NC 27709, USA

⁴ Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia

*equal contribution

#corresponding author

Corresponding author:

Valentina Mosienko

Medical Science Building

University Walk, BS8 1TD, Bristol

United Kingdom

Tel: +441173312222

Email: valentina.mosienko@bristol.ac.uk

Short running title:

New tools to manipulate the serotonergic system

Key words: serotonergic system, Cre recombinase, optogenetics, Pet1, SERT, TPH2

Abstract

In the brain, serotonin (5-hydroxytryptamine, 5-HT) controls a multitude of physiological and behavioral functions. Serotonergic neurons in the raphe nuclei give rise to a complex and extensive network of axonal projections throughout the whole brain. A major challenge in the analysis of these circuits is to understand how the serotonergic networks are linked to the numerous functions of this neurotransmitter. In the past, many studies employed approaches to inactivate different genes involved in serotonergic neuron formation, 5-HT transmission or metabolism. Although these approaches have contributed significantly to our understanding of serotonergic circuits, they usually result in life-long gene inactivation. As a consequence compensatory changes in serotonergic and other neurotransmitter systems may occur and complicate the interpretation of the observed phenotypes. To dissect the complexity of the serotonergic system with greater precision, approaches to reversibly manipulate subpopulations of serotonergic neurons are required. In this review, we summarize findings on genetic animal models that enable control of 5-HT neuronal activity or mapping of the serotonergic system. This includes a comparative analysis of several mouse and rat lines expressing Cre or Flp recombinases under *Tph2*, *Sert*, or *Pet1* promoters with a focus on specificity and recombination efficiency. We further introduce applications for Cre-mediated cell-type specific gene expression to optimize spatial and temporal precision for the manipulation of serotonergic neurons. Finally, we discuss other temporally regulated systems, such as optogenetics and DREADD approaches to control 5-HT neuron activity.

Contents

1. Introduction	4
2. Targeted expression of Cre and Flp recombinases in serotonergic cells.....	5
2.1. Cre recombinase expression driven by the <i>Sert</i> promoter	7
2.1.1. Knock-in SERT-Cre	7
2.1.2. BAC-SERT-Cre.....	8
2.2. Recombinase expression driven by the <i>Pet1</i> promoter	8
2.2.1. ePet1-Cre	8
2.2.2. ePet-Flpe	8
2.2.3. Pet1 ²¹⁰ -Cre	8
2.2.4. BAC-Pet1-Cre	9
2.2.5. BAC-Pet1-CreERT2.....	9
2.3. Cre recombinase expression driven by the <i>Tph2</i> promoter.....	10
2.3.1. BAC-TPH2-CreERT2.....	10
2.3.2. BAC-TPH2-CreERT2.....	10
2.3.3. BAC-TPH2-iCreERT2.....	10
3. Targeting defined serotonergic subpopulations	11
3.1 Dual recombinase strategies	11
3.2. Viral mediated gene transfer.....	12
3.2.1. Anterograde transport.....	13
3.2.2. Retrograde transport.....	13
3.2.3. Transsynaptic transport.....	14
4. Temporal control of gene expression within the serotonergic system	15
4.1. Inducible Cre-expressing mouse lines	15
4.2 Tetracycline-sensitive systems.....	15
4.3 DREADDs	16
4.4. Optogenetics	17
Summary.....	19

1. Introduction

Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine that acts as a neurotransmitter in the central nervous system (CNS) and as an autacoid in the periphery. Serotonin synthesis in the CNS is restricted to serotonergic neurons, which originate from the raphe nuclei of the brain stem and extend vast axonal projections into different areas of the brain and spinal cord. Its synthesis is a two-step reaction. Tryptophan hydroxylase (TPH) 2 catalyzes the first, rate-limiting step in the CNS, in contrast to TPH1, which is active in the periphery.¹⁻³ *Tph2* is expressed exclusively in serotonergic neurons within the brain and in the enteric nervous system in the gut but not in other peripheral organs or neuronal cell types.²⁻⁶ Serotonin packaging into vesicles is mediated by vesicular monoamine transporter (VMAT) 2, which is expressed in monoaminergic neurons.⁷ Serotonin actions are mediated by its numerous receptors, that have different expression patterns within the CNS, including presynaptic locations.^{8, 9} For example, 5-HT_{1A} autoreceptors, which are expressed on soma and dendrites of serotonergic neurons, mediate inhibition of cell firing.¹⁰ Another important component of serotonergic neurons is serotonin transporter (SERT), which mediates 5-HT uptake.¹¹ In the brain of adult animals, SERT is mainly expressed on 5-HT producing neurons of the raphe nuclei and astrocytes.¹² During development, transient SERT expression in the brain is broader and includes nonserotonergic neurons in limbic, thalamic and retinal areas.¹³ Furthermore, SERT is located in a number of peripheral cells, such as platelets, adrenomedullary chromaffin cells, crypt cells in the gut, lung, liver, and testis.^{14, 15} SERT expression is therefore not restricted to serotonergic neurons.

Serotonergic neurons of the raphe nuclei are organized in groups, which are distinguished by their different anatomical location, axonal trajectories and physiological properties.¹⁶⁻¹⁸ The more rostrally located serotonergic cell groups, B6-B9, project to forebrain regions, whereas caudal serotonergic groups, B1-B5, project towards the spinal cord and brain stem.¹⁹ Although anatomically clustered, groups of serotonergic neurons are not homogenous in their electrophysiological properties and consist of different subpopulations, which are not fully characterized so far.^{20, 21}

During brain development, serotonergic neurons arise from distinct units of the neural tube, named rhombomeres (r1-r3 and r5-r7).¹⁹ Developing 5-HT neuronal precursors along the rhombomeres express the PC12 ETS domain-containing transcription factor 1 (Pet1)

and LIM homeobox transcription factor 1 (Lmx1b) which are involved in serotonergic neuron differentiation. Lmx1b precedes Pet1 expression, and is also expressed in dopaminergic progenitors and neurons.²² Pet1 was thought to be a specific marker of differentiated post-mitotic serotonergic neurons.^{16, 23-25} However, more recent studies indicated that Pet1 is also active in some non-serotonergic cells in adult and developing brain and in peripheral organs such as adrenal glands, the 5-HT-synthesizing enterochromaffin cells of the intestine, developing kidney, and pancreas.^{26, 27}

The fact that development of serotonergic neurons, 5-HT synthesis, release and reuptake require expression of multiple specific genes was used for the analysis of serotonergic circuits. Mouse models were engineered to express different reporters specifically in serotonergic neurons, such as the transgenic ePet-EYFP²⁸, the TPH2-GFP knock-in,²⁹ and the TPH2-LacZ knock-in mouse lines.³⁰ These models have been employed in various *in vivo* and *in vitro* studies to examine electrophysiological properties and morphology of 5-HT neurons.²⁸⁻³⁰ To manipulate the serotonergic system, various strategies for enhancement or inhibition of neuronal activity have been used. Besides numerous pharmacological interventions, a number of studies employed genetic approaches to inactivate or overexpress different genes involved in serotonergic neuron formation, 5-HT transmission and metabolism.³¹⁻³⁸ The behavior and physiological consequences of life-long alterations in serotonergic signaling in the brain in these models were recently reviewed.³⁹⁻⁴²

The characterization of these genetic models contributed greatly to our understanding of serotonergic circuits. However, genetic approaches which result in life-long changes in gene expression (for example full knockouts or constitutive overexpression models) may induce compensatory mechanisms in other neurotransmitter systems, thus making it impossible to assess 5-HT function *per se*. Moreover, these models do not provide an opportunity to study functions of specific subpopulations of 5-HT neurons. In this review we summarize new tools which provide higher specificity and temporal control to study serotonergic circuitry.

2. Targeted expression of Cre and Flp recombinases in serotonergic cells

To manipulate serotonergic neurons in the CNS of mice, many studies have made use of the standard Cre-LoxP approach for cell type-specific recombination. The Cre protein is a

site-specific DNA recombinase, that catalyses the recombination between two 34 bp long loxP sequences.^{43, 44} Cre-dependent recombination in conjunction with LoxP-flanked target genes or stop cassettes can inactivate or activate the expression of a gene of interest (GOI) respectively. Over the last decade, a number of transgenic and knock-in Cre-expressing mouse lines have been generated. To direct transgene expression with the same developmental timing and spatial expression patterns as certain endogenous genes, bacterial artificial chromosomes (BACs) have also been widely used.⁴⁵ BACs are DNA constructs, which are capable to host the DNA fragments of >350 kilobase pairs with a high degree of stability.^{46, 47} Therefore, they are suitable for inserting large promoter regions including distant regulatory elements to drive Cre expression in specific cell populations.^{48, 49} Alternatively, knock-in approaches can be applied to control expression of the recombinase using the same machinery which controls expression of cell specific genes. In these cases the expression pattern is much more accurate and does not require time-consuming isolation and characterization of the promoter.⁵⁰ Most importantly, the knocked-in transgene does not generate additional mutations at an unknown locus as classical randomly integrated transgenes do. Of note, during the knock-in approach one allele of the gene in which Cre is inserted will be disrupted leading to a heterozygous knockout of this gene unless the transgene is linked via a 2A-peptide sequence at the 3'-end of the endogenous driver gene. For some genes, such as *Tph2*, the heterozygosity does not evoke behavioral alterations⁵¹, whereas for other genes, e.g., *Sert*, the deletion of one allele results in changes in neurochemistry and physiology (see below 2.1.1) and should be considered as an additional factor to be controlled for. Once a specific Cre line is successfully generated, the expression of recombinase can be functionally characterized by crossbreeding with Cre-dependent reporter strains, such as Rosa26loxP-STOP-lacZ or ROSA26loxP-stop-EYFP.^{52, 53} which start to express β -Galactosidase (β -Gal) or EYFP, respectively, once Cre recombinase is active. Co-localization analysis of reporter expression and serotonergic markers is an important step in evaluating the specificity and confirming the efficiency of Cre-dependent recombination. In case of inducible Cre-ERT2 models, a chimeric protein consisting of a codon-optimized Cre recombinase fused to a triple mutant form of the human estrogen receptor (ERT2) is expressed in targeted cells. The mutant receptors no longer bind endogenous estradiol, but instead recognize the synthetic ligand Tamoxifen (TMX). Upon TMX administration, the recombinase gains access to the nuclear compartment and initiates recombination,⁵⁴ thereby permitting temporal control of gene manipulation.

Another enzyme, flippase (Flp), which works similar to Cre and mediates DNA recombination between 34bp-long Flp recognition target (FRT) sites, has also been used in such approaches (reviewed in⁵⁵). Available Cre and Flp transgenic mouse lines for the serotonergic system are summarized in Table 1, and discussed below in more detail.

2.1. Cre recombinase expression driven by the *Sert* promoter

2.1.1. Knock-in SERT-Cre

Among the first published lines targeting specific neurotransmitter systems is the SERT-Cre mouse line, generated by knocking in Cre into the *Slc6A4* locus (gene coding for SERT) by the group of R. Hen.⁵⁰ In the raphe, 99% of cells which underwent recombination were TPH-positive, and nearly all serotonergic neurons were recombined. These results indicate a high recombination efficiency and specificity in the raphe of this SERT-Cre mouse line. This line has been widely used for different applications, including studies of heart development, effects of selective serotonin re-uptake inhibitors (SSRIs), sudden infant death syndrome, depression, addiction, development, and metabolism.⁵⁶⁻⁶⁰ For example, Narboux-Nême and colleagues disabled serotonergic transmission by crossing SERT-Cre to VMAT2^{fl/fl} mice which led to a major (~95%) depletion of central 5-HT, but not other monoamines, through excision of the VMAT2 in SERT-positive cells.⁶¹ However, this SERT-Cre line has several limitations. Firstly, due to the disruption of the *Slc6A4* this SERT-Cre mouse represents a heterozygous knockout resulting in a mild behavioral and biochemical phenotype⁵⁰ and therefore, proper controls (optimally SERT-Cre⁺ GOI^{fl/fl} versus SERT-Cre⁺ GOI^{wt/wt}) should be used in experiments. Another limitation of this line is Cre recombination occurring in non-serotonergic neurons of the thalamus, the cingulate cortex, and the CA3 region of the hippocampus (summarized in the Table1) due to transient SERT expression in these regions during early development.⁶² Furthermore, the SERT-Cre line is prone to germ-line transmission of the recombined allele, due to SERT-driven Cre expression in male germ cells.⁵⁹ This may lead to the generation of a total, instead of a cell-type specific, knockout. By crossing SERT-Cre and ObRb^{fl/fl} mice the group of G. Karsenty inactivated the leptin receptor b (LepRb) in serotonergic neurons.³⁰ Based on the experiments performed in these mice they postulated that leptin regulation of appetite occurs by inhibition of 5-HT synthesis in the brain. However, a detailed analysis by other group could not confirm the expression of LepRb in serotonergic neurons and it

was supposed that the phenotypes, observed by Karsenty group were most probably resulting from total instead of conditional LepRb knockout⁵⁹.

2.1.2. BAC-SERT-Cre

Three BAC-SERT-Cre transgenic mouse lines were generated in frames of GENSAT project (<http://www.gensat.org/index.html>).⁴⁹ In 2 founder lines (E33/E35) Cre expression was restricted to adult serotonergic neurons, whereas in the third line (E124) Cre expression was also observed in corticothalamic and thalamocortical neurons.^{49, 63} Moreover, in the E33 and E124 lines of BAC-SERT-Cre mice, Cre expression was observed in the developing visual system⁶⁴ and the upper layers of the barrel cortex,⁶⁵ respectively. These findings confirm SERT expression by non-serotonergic neurons during development, as shown earlier.^{13, 62} Taken together, BAC-SERT-driven Cre expression targets all serotonergic neurons, however, ectopic SERT expression during development and developmental recombination in transgenic SERT-Cre lines must be considered.

2.2. Recombinase expression driven by the *Pet1* promoter

2.2.1. ePet1-Cre

Using a 40kb-long DNA region upstream of the *Pet1* gene containing an enhancer essential for proper *Pet1* expression, the laboratory of E. Deneris generated an ePet1-Cre line which enables Cre-mediated recombination restricted to all 5-HT neurons.²⁸ Within the CNS, no ePet activity was detected outside the serotonergic system, however the analysis of LacZ expression in the periphery of R26R^{ePet-Cre} mice revealed Cre-dependent recombination in some cells of skin, gut, pancreas, and cardiac neural crest.

2.2.2. ePet-Flpe

A Flp recombinase driver line, ePet-Flpe, was generated in the laboratory of S. Dymecki⁶⁶ with the same ePet construct used by the Deneris' group previously to generate the ePet-Cre line.²⁸ In the raphe of ePet-Flpe mice, the activity of Flp is high and mediates recombination in most 5-HT raphe neurons.⁶⁶

2.2.3. Pet1₂₁₀-Cre

To control somatic recombination in the *Pet1* lineage more reliably, the group of M. Pasqualetti generated mice expressing Cre under control of a large 210kb-long fragment of the *Pet1* genetic locus, including all putative regulatory regions.²⁶ Pet1₂₁₀-Cre transgenic

mice revealed the existence of non-serotonergic neuronal populations, which express Pet1 within the raphe, mostly in the B8 and B9 cell groups. Cre expression was also detected in embryonic kidney and pancreas, demonstrating that Pet1₂₁₀-Cre mice are useful to study rather Pet-1 expressing lineages other than 5-HT neurons in particular (Table 1). Based on these findings, the specificity of other Pet-1 driven Cre lines and reporters, such as ePet1-EYFP,²⁸ should be reevaluated in these non-serotonergic neuronal populations and peripheral tissues.

2.2.4. BAC-Pet1-Cre

Another BAC-based Pet1-Cre mouse line was generated by the group of Y.Q. Ding⁶⁷ by insertion of the Cre coding sequence into the Pet1 locus. After crossing with Rosa26 reporter mice, X-Gal staining and double immunostaining for Cre and 5-HT revealed raphe nuclei-specific Cre expression.

The efficiency of Cre recombination was assessed by breeding Pet1-Cre mice with carriers of a floxed Lmx1b gene. In the resulting mice, 5-HT and SERT were almost absent in the whole brain, except for a single 5-HT-positive neuron found in the dorsal raphe (DR) (1%). It was thereby shown that adult Lmx1b^{Pet1-Cre} mice lack essentially all 5-HT neurons and terminals. The HPLC measurements still revealed the presence of residual 5-HT, although at concentrations 10 fold lower than in wild type animals. It is unclear whether this is due to undetected serotonergic neurons that did not undergo recombination or the HPLC results reflect contamination by blood 5-HT due to insufficient perfusion with saline before tissue isolation. Information about non-serotonergic Cre expression was not provided for this line.

2.2.5. BAC-Pet1-CreERT2

The same group also generated a BAC-Pet1-CreERT2 transgenic mouse line that allows TMX-inducible recombination.⁶⁸ In this model, recombination was shown to be specific for serotonergic neurons in the DR and raphe magnus (RM), but only 85% of TPH2 expressing neurons co-expressed the floxed reporter gene after TMX treatment. Crossbreeding of this Pet1-CreERT2 line with Lmx1b^{fl/fl} mice led to 40% reductions in brain 5-HT levels and downregulation of serotonergic markers.⁶⁸

One limitation of this mouse line is its FVB/N background used for the generation of founder lines. Most floxed mice are generated on a C57BL/6 background, which has become the most widely used strain for developmental and behavioral studies. The FVB/N line was reported to have higher than C57BL/6 mouse line locomotor activity, anxiety, and basal body temperature and is homozygous for the *Pde6brd1* allele, causing retinal degradation (<http://jaxmice.jax.org/strain/001800.html>). As a consequence, most FVB/N

mice are blind⁶⁹ and thus, not suitable for behavioral experiments. This phenotype might also be inherited after crossing the Pet1-CreERT2 line to other strains and might have an unpredictable impact on experimental results.

2.3. Cre recombinase expression driven by the *Tph2* promoter

2.3.1. BAC-TPH2-CreERT2

After discovery of the brain specific TPH isoform⁶ the *Tph2* promoter was used to direct Cre expression selectively to 5-HT neurons. In 2009, the group of D. Bartsch applied a BAC-based transgenic approach to create TMX-inducible TPH2-CreERT2 mice.⁷⁰ Besides higher specificity of the *Tph2* promoter for serotonergic neurons in comparison to SERT or Pet1, use of CreERT2 in this line allows recombination at any stage of development or adulthood. The same BAC-based construct was also later used to generate a TPH2-CreERT2 rat line.⁷¹ High specificity of Cre expression upon TMX treatment was demonstrated in both TPH2-CreERT2 mouse and rat lines. However, rats showed a lower recombination efficacy compared to mice (77% in rats vs. 90% in mice) (Table 1).

2.3.2. BAC-TPH2-CreERT2

A comparable TPH2-CreERT2 mouse line, based on a BAC construct, was also generated by Yadav and colleagues⁷² to study leptin-dependent 5-HT control of appetite. Characterization of this line after breeding with Rosa26loxP-STOP-lacZ mice⁵² and TMX treatment revealed β -Gal staining in DR, median raphe (MnR), and caudal raphe (CR) nuclei of the brainstem but not in hypothalamic or other regions. The specificity for serotonergic neurons within these areas has not been determined however.

2.3.3. BAC-TPH2-iCreERT2

A similar mouse line (TPH2-iCreERT2) was independently generated by B. Gloss, (<http://jaxmice.jax.org/strain/016584.html>). However in this case, an improved version of Cre gene (iCre) was employed by applying mammalian codon usage and by lowering the high CpG content of the prokaryotic coding sequence, thereby reducing the chances of epigenetic silencing in mammals.^{73, 74}

We have confirmed iCreERT2-mediated recombination within the DR, but not in the other brain regions using crossbreeding of this mouse line to Rosa26loxP-STOP-lacZ,⁵² ROSA26loxP-stop-EYFP,⁵³ and Rosa26loxP-STOP-tdTomato (Jackson Laboratories, B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J Stock Number: 007914) reporter mice

(Fig.1 A, B, C). Moreover, injection of an adeno associated virus (AAV), EF1a-DIO-CheTA-EYFP, into the medial DR indicated effective Cre-mediated recombination in TPH2-iCreERT2 mice (Fig.1D). However, a more detailed analysis of the specificity and efficacy of Cre expression in this line is still pending.

In summary, a wide repertoire of genetic tools to target Cre-mediated recombination to serotonergic neurons is now available (Table 1). *Pet1*-Cre and SERT-Cre lines are well characterized and represent useful tools to study the serotonergic system, whereby *Sert*-driven Cre lines have higher specificity and recombination efficiency than *Pet1*-driven transgenes, as recently demonstrated in the comparative study of VMAT^{Sert-Cre} and VMAT^{Pet1-Cre} mice.⁷⁵ However, both promoters are not exclusively selective for the serotonergic lineage, whereas *Tph2*-driven Cre expression represents a more specific tool and should be regarded as a better model to target 5-HT-producing neurons specifically in the future. Additionally, the recent availability of the *Tph2*-driven rat Cre line⁷¹ allowed researchers to apply the more sophisticated behavioral tests for higher cognitive functions that have been already developed for use in rats, but not in mice.

3. Targeting defined serotonergic subpopulations

As described in the sections above, precise targeting of a transgene to most serotonergic neurons can be performed successfully using several different mouse lines, albeit with some limitations. However, the serotonergic system itself is heterogeneous and includes various subpopulations of neurons with different connectivity, functions, and developmental origins. Manipulating these subpopulations selectively requires more advanced methods.

3.1 Dual recombinase strategies

Making use of newly developed genetic technologies, the group of S. Dymecki, identified rhombomere (r)-defined 5-HT sublineages that differ in gene expression with respect to progenitor and precursor cells.⁶⁶ These investigators have created a novel dual recombinase-responsive indicator allele, RC-Fela, and a Flpe recombinase driver line, ePet-Flpe. While RC-Fela serves as recombination reporter, ePet-Flpe directs recombination to *Pet1*-expressing 5-HT precursors. Combining RC-Fela with ePet-Flpe and Cre lines, specific for particular rhombomeres, enables isolation and manipulation of specific 5-HT neuronal subpopulations arising from these rhombomeres. For example, *En1*-Cre mice expressing Cre under the *engrailed 1* (*En1*) promoter were used to study the subpopulation of 5-HT neurons originating from r1. In a comparable approach, the

intersectional alleles RC-FrePe and RC-FPD_i were used to identify 5-HT neurons mediating breathing reflex control.⁷⁶ These triple transgenic animals provide new tools for *in vivo* manipulation of specific 5-HT subpopulations and for “functional mapping” studies. In another study using the same selective dual recombinase strategy, Kim and colleagues directed tetanus toxin light chain (tox) synthesis to serotonergic subpopulations and thereby inhibited vesicular neurotransmission in those neurons.⁷⁷ By recombinase expression under *Pet-1* and *En1* promoters in En1-Cre, ePet1-Flpe, RC-PFtox mice, they targeted the subpopulation of Pet1-descendant 5-HT neurons arising from serotonergic progenitors in r1. Tox action was thereby restricted to cells expressing both Cre and Flpe recombinases and required two recombination events. Using the described dual-recombinase technique, higher specificity (targeting of individual serotonergic subgroups) was achieved when compared to single-recombinase or conventional transgenic methodologies.

3.2. Viral mediated gene transfer

An alternative to transgenic approaches is virus-mediated gene transfer into specific brain structures. Spatial control of vector delivery can be achieved by using the appropriate stereotaxic injection coordinates.

Adenoviruses were among the first viruses to be successfully used for the specific infection of DR.⁷⁸ In this approach, stereotaxic injection of a Cre-expressing adenovirus (AdCre)⁷⁹ into the DR of a Cre-dependent LacZ reporter mouse line CAG-LoxP-stop-LacZ⁸⁰ led to the expression of Cre recombinase in approximately 12% of serotonergic neurons. Within 9 days after the injection, 43% of Cre-expressing 5-HT neurons were also positive for LacZ, confirming the validity of the method to target Cre-recombination throughout the DR.

Lentiviruses have also been applied to label serotonergic neurons. To drive the expression of the EGFP exclusively in serotonergic neurons, an optimized *Tph2* promoter with a two-step transcriptional amplification design was employed.⁸¹ Stereotactic injections of such viruses to medulla oblongata covering some of the midline and ventral raphe led to EGFP expression that was 97% colocalized with TPH expression. Of particular importance is the ability of lentiviruses to stably integrate into the genome of non-dividing cells, which is useful for lineage tracing.

Meanwhile more advanced techniques combining AAV and transgenic approaches have been developed to enable highly selective transgene expression. For example, by injecting a double-floxed AAV with an inverse open reading frame for a channelrhodopsin2-

mCherry fusion protein (AAV2 DIO ChR2-mCherry) into the raphe obscurus (RO) of ePet-Cre mice, DePuy and colleagues showed that roughly half of 5-HT neurons in the raphe area were infected and 97% of infected cells were serotonergic.⁸² Recently, sindbis virus, canine adenovirus serotype 2 (CAV2), and rabies viruses have been developed for anterograde, retrograde, and transsynaptic retrograde transport, respectively, and used to study serotonergic circuitry.⁸³⁻⁹⁰

3.2.1. Anterograde transport

Suzuki et al. injected a GFP-tagged sindbis virus into the DR for anterograde tracing of single serotonergic neurons to the olfactory bulb.⁸⁷ The advantage of using sindbis virus is its high transfection efficiency in the CNS and its capacity to carry large amounts of genetic material. However, this virus is suitable only for acute *in vivo* work as infected neurons start degenerating 7 days after viral injection.⁹¹

3.2.2. Retrograde transport

For retrograde tracing studies, Wu et al. injected retrogradely transported CAV2-Cre virus into the Nucleus tractus solitarius (NTS) of conditional TPH2^{lox/lox} mice.⁹⁰ Upon transport from the injection site to the cell bodies, Cre inactivates the *Tph2* gene, specifically in neurons with projections to the injected area. TPH2 staining was decreased in RO and RM serotonergic neurons by 60-80%, while DR neurons were unaffected. As a result, 5-HT levels in the NTS of injected TPH2^{lox/lox} mice were decreased by about 75%. In combination with ablation of specific neuropeptide-expressing neurons, this study allowed elucidation of the serotonergic mechanisms of feeding and body weight regulation.⁹⁰

Interestingly, many AAVs, though not all, show a robust capacity for retrograde infection and subsequent transgene expression in mice. To isolate neuromodulatory serotonergic neurons that send axons to the basolateral amygdala (BLA), Rothermel et al.⁸⁵ used recombinant, pseudotyped AAVs (rAAVs) engineered to improve transduction efficiency and tissue tropism using capsid genes from other AAV serotypes (e.g., AAV2/1). The applied virus carried a Cre-dependent expression switch (2/9.DIO.ChR2-EYFP) to allow ChR2-EYFP expression only in Cre-positive cells. Stereotaxic injection into the BLA of SERT-Cre mice resulted in ChR2-EYFP expression in a number of raphe neurons, mainly in the DR.

3.2.3. Transsynaptic transport

To analyze monosynaptic inputs to DR and MnR serotonergic neurons, Ogawa and colleagues used a retrograde transsynaptic system based on a modified rabies virus that initially infects only cognate receptor (TVA protein) expressing cells and lacks a glycoprotein required for transsynaptic spread.⁸³ SERT-Cre mice⁵⁰ were injected with two helper viruses expressing the glycoprotein and TVA after Cre recombination into either DR or MnR.⁸⁸ This allowed the virus to spread transsynaptically to cells with direct synaptic contact to DR or MnR serotonergic neurons. Here, 95.8 % of infected TVA expressing cells were shown to be serotonergic and 30.5 % of 5-HT neurons were infected and expressed TVA. A small number of neighboring 5-HT-containing neurons were targeted as well.⁸³ A rabies virus tracing strategy in SERT-Cre mice was also used in other studies to generate a whole-brain atlas of putative monosynaptic inputs onto forebrain-projecting DR and MnR serotonergic neurons or to characterize the distinct excitatory, inhibitory, and peptidergic inputs to the DR.^{84, 86, 89} However, released rabies virus can be taken up by adjacent terminals that may or may not be synaptically connected.⁹² Classification of connectivity patterns will permit further functional dissection of the serotonergic system and enable analysis of the physiological relevance of specific input circuits.

Taken together, viral delivery entails some disadvantages in comparison to transgenic animals such as postoperative recovery, limited injection volumes, and challenges associated with injection accuracy. Moreover, adeno⁹³⁻⁹⁷ and sindbis⁹¹ viruses might evoke immune responses and inflammation. The regular serotypes (1-10) of AAV cause minimal *in vivo* immune response,⁹⁸ but some may cause gliosis⁹⁹ and neurological deficits. Lentiviruses are more conservative in this respect and pose less of a risk of CNS damage. As an advantage viruses permit much higher expression levels of transgenes and enable retrograde transport enabling labeling and manipulation of neuronal subpopulations defined by their axonal terminals. Furthermore, viral mediated transgene expression represents a useful tool to deliver light-sensitive proteins for optogenetic approaches (see below). Though conventional viral vectors cannot incorporate very large transcriptional control units similar to BACs, they are optimal for the delivery of small transgenes such as Cre recombinase or Cre-dependent expression cassettes. Due to the ease and low cost of viral production in comparison to transgenic animals, viral methodology allows facile implementation of new genetic tools into experimental designs.

4. Temporal control of gene expression within the serotonergic system

4.1. Inducible Cre-expressing mouse lines

Performing a genetic manipulation at a selected time point during the lifetime allows the study of age-specific biochemical and behavioral effects within the serotonergic system. Several inducible Cre lines that enable excision or activation of genes at chosen time points within the serotonergic system are described in the sections above^{49, 68, 70, 71, 100} and are summarized in Table 1. However, these are not without limitations. Recombination mediated by Cre or other recombinases is an irreversible and relatively slow process. Furthermore, repeated TMX injections are necessary to permit drug delivery to all serotonergic neurons and to induce appropriate recombination rates. While TMX is FDA (U.S. Food and Drug Administration) approved, administration at doses higher than 150 mg/kg has been shown to evoke toxic effects in mice.^{101, 102} Moreover, it should be taken into account that TMX is a strong estrogen receptor antagonist. Therefore, minimal doses of TMX should be used. Moreover, recent studies demonstrated that systemic activation of CreERT2 might elicit hematological toxicity.^{101, 102} Therefore, use of proper controls, such as Cre⁺GOI^{wt/wt} + TMX is essential.

4.2 Tetracycline-sensitive systems

Audero et al. suppressed serotonergic firing by overexpressing 5-HT_{1A} autoreceptors reversibly in transgenic mice,¹⁰³ using the tetracycline-Off (tet-Off) system.^{104, 105} Double transgenic mice were generated by breeding mice carrying the *tet*-promoter (Ptet) inserted upstream of the endogenous 5-HT_{1A} receptor gene (*5-Htr1a*^{tetO} allele) with mice encoding the tetracycline transactivator (tTA) inserted downstream the ATG codon of the endogenous *Slc6A4* (gene coding for SERT). tTA is an artificial transcription factor, that binds to Ptet, which in turn, mediates the overexpression of a GOI, in this case the *5-Htr1a*. Administration of Doxycycline (Dox, a stable tetracycline analogue) in this model leads to the prevention of transactivation of 5-HT_{1A} receptors and, therefore, allows temporal control of their expression. Although 5-HT specificity is based on the *Sert* promoter, which might be also active in non-serotonergic cells, 5-HT_{1A} receptor overexpression in double-transgenic animals is restricted to raphe nuclei of the mid- and hindbrain. However, it has not been determined whether the affected cells are all serotonergic.

Weber et al. designed a comparable ON/OFF system for genetic manipulations in 5-HT neurons.¹⁰⁶ Similar to Audero and colleagues, they generated double-transgenic mice encoding tTA under the *Tph2* promoter and a nLacZ reporter under the control of the tet-response system (TPH2-tTA/Ptet-nLacZ mice). Dual-label fluorescence immunohistochemistry identified LacZ expressing cells as serotonergic. Extraserotonergic brain regions were largely devoid of X-Gal staining, except for sparse β -Gal activity in the hypothalamus and beneath the aqueduct. Additionally, in the raphe, a few TPH2-negative cells were β -Gal positive, revealing some nonspecific gene targeting. Dox administration completely suppressed Ptet-mediated reporter expression and subsequent Dox withdrawal resulted in reactivation.

When 5-HT-specific tTA mice are mated with Ptet-Cre/loxP-flanked target gene animals, spatially controlled, inducible gene deletion (TPH2-tTA/Ptet-Cre/loxP) can be achieved, comparable to TMX-inducible CreERT2 systems. In addition to the spatial control by the chosen promoter, temporal control of gene expression is possible with the described tet-Off methodologies. Unlike the Cre/loxP system, gene manipulations are reversible. However, Ptet-controlled gene expression after Dox withdrawal occurs with a delay, depending on the animal's age, Dox concentration, duration of treatment, and many other factors that have to be controlled for. In contrast to i.p. administration of TMX, Dox treatment is more suitable for behavior studies as it can be added to the drinking water diminishing effect of stress. Since Dox has a bitter taste, sugar or sweeteners are often added to Dox solutions that may lead to an increase in drinking volume, additional body weight gain, or other unexpected behavioral outcomes.

4.3 DREADDs

A different method for efficient modulation of signal transduction in selected neurons is the introduction of Designer Receptors Exclusively Activated by Designer Drugs (DREADD) – engineered G-protein-coupled receptors that are activated by otherwise inert synthetic ligands. During recent years, several modifications of this technique have been used for *in vitro* and *in vivo* experiments.¹⁰⁷⁻¹⁰⁹ The example below made use of a Gi-DREADD (Di), a synthetic Gi/o-protein-coupled receptor that activates inwardly rectifying potassium channels upon stimulation with the compound clozapine-N-oxide (CNO) resulting in hyperpolarization and transient neuronal silencing.¹¹⁰

To study the influence of serotonergic activity on homeostatic control, Di was expressed via previously described dual-recombinase methodology with cell-subtype precision.^{66, 77,}

¹⁰⁹ A combination of the single recombinase-responsive allele RC-PDi, responsive to Cre, with SERT-Cre was used to express Di in nearly all serotonergic neurons. These cells responded to CNO with hyperpolarization that led to the suppression of cell excitability. Furthermore, incorporation of a Cre-inducible reporter allele, RC-rePe, allowed visualization of Di expressing cells by GFP. Beyond serotonergic neurons, a population of extraserotonergic neurons in the thalamus was shown to express Di as well, due to presence of SERT-positive cells in this brain region. Current-clamp membrane potential recordings from cultured serotonergic neurons of the lower brainstem revealed a ~40 % reversible reduction in firing rates in Di expressing neurons after CNO exposure. Administration of CNO to transgenic animals resulted in rapid attenuation of chemoreflex, as well as a decrease in core body temperature representing vital physiological functions of 5-HT.¹⁰⁹ DREADDs enable ligand-inducible inhibition of SERT-expressing neurons that is reversible within hours, and serves as model for functional mapping of neurons. CNO-mediated inhibition happens within a shorter time frame as compared to Dox- or TMX-inducible systems. At the same time, inertness of CNO has been questioned by others due to its redox partners and their biological effects.¹¹¹ If CNO is not effectively eliminated by the kidneys, it can be reduced to the tertiary amine clozapine *in vivo*.^{112, 113} Various tertiary amine reduction routes generate compounds that efficiently act as agonists for DREADDs and a number of other receptors. In turn, receptor-mediated intracellular signaling pathways may be activated and impact animal physiology.¹¹⁴ These other possible actions of CNO metabolites are capable of reducing designer receptor-based cell and effect specificity and should be excluded by the use of appropriate controls. As another word of caution, all G-protein coupled receptors when artificially expressed at high levels are able to produce downstream coupling events without ligand presence. Various groups, including ourselves have observed this with DREADDs (S. Kasparov, unpublished observations). Therefore, it is critical to control for changes in cellular biochemistry or physiology in animals expressing DREADDs before CNO application.

4.4. Optogenetics

Optogenetics is another current technique to modulate neuronal function that does not involve chemical ligands and enables much higher temporal resolution.¹¹⁵ Optogenetics enables researchers to manipulate firing rates of specific neuronal populations and to measure the outcome using physiological and behavioral readouts *in vivo*. For tight optical control of neuronal excitability, light-sensitive channels or light-driven ion pumps are expressed in genetically defined neurons. The most commonly used optogenetic actuator

is the non-selective cation channel channelrhodopsin, ChR2, and its derivatives. Using BAC technology, Zhao and colleagues generated a mouse line expressing ChR2 driven by the *Tph2* promoter, TPH2-ChR2-EYFP.¹¹⁶ Co-localization of the reporter EYFP with 5-HT was shown for serotonergic neurons in the DR (¹¹⁶ and Fig.2A). Transgene expression was moderate in MnR and DR as approximately 15% of TPH2-positive cells were EYFP-negative.¹¹⁶ Electrophysiological recordings from the EYFP-positive neurons showed responsiveness to blue light. It is important to stress that ChR2 and similar proteins have to be expressed in the target cells at fairly high levels to enable efficient control of excitability. We employed this mouse model to study the impact of descending 5-HT-ergic control on sensory transmission in the spinal cord, based on previous studies that revealed a dual role for 5-HT in inhibition and facilitation of nociceptive input.¹¹⁷⁻¹²⁰ These earlier studies relied mainly on gross lesions, broadly acting pharmacological manipulations, and electrical stimulation of the DR, techniques with obvious limitations such as compensatory re-wiring of the pathways, impact on the release of other neuromodulators,^{121, 122} and co-activation of non-5-HT neurons and fibres of passage.¹²³ In theory, optogenetic stimulation of DR 5-HT neurons should help to overcome these limitations.¹²⁴ In anaesthetized TPH2-ChR-EYFP mice, optogenetic stimulation of 5-HT neurons in dorsolateral DR (coordinates from lambda: 0.3 mm ML, -1 mm AP, -3.4 mm DV; blue light stimulation: 10 msec ON, 10 msec OFF, 20 sec, 20 mV) did not significantly alter the expression of c-Fos, a marker of neuronal excitability,¹²⁵ in the dorsal horn of the spinal cord (Fig. 2B), which serves as an index of the nociceptive input.¹²⁶ Despite the refinement of the targeting techniques to specifically excite DR 5-HT neurons, the impact of serotonergic innervation of the spinal cord on nociceptive transmission remains ambiguous. Our negative finding might also indicate that different 5-HT subpopulations (that we could have stimulated simultaneously) have opposing effects on the nociceptive control so as to cancel each other out.

To refine the spatial specificity, mouse lines expressing Cre recombinase under cell-specific promoters, in combination with viral delivery can also be used for optogenetic experiments. Such an approach was used in the study by Dugue et al., where viral vectors were injected into transgenic SERT-Cre mice (described above).¹²⁷ In this study, response thresholds in awake behaving SERT-Cre mice following injection of viruses carrying Cre-dependent ChR2-EYFP into the DR (coordinates from bregma: 0 mm ML, 4.4 to -4.7 mm AP, -2.8 to -2.9 mm DV, with a 34° caudal angle) were higher compared to control mice in the von Frey assay, a simple test of mechanosensitivity.¹²⁸ The work of Dugue et al.¹²⁷ and our studies (Fig. 2B-D) show that the response might differ between anesthetized and conscious animals, and that the roles of different serotonergic subpopulations may not be

identical.

Delivery of light-sensitive channels is possible by combining the above described mouse lines expressing Cre under cell-type specific promoters with recently developed mouse lines expressing various opsins in a Cre-dependent manner.¹²⁹ However, due to the heterogeneity of the serotonergic system, this will not allow precise targeting of particular subpopulations of 5-HT neurons.

Finally, since rat transgenics are much less developed, injection of viral vectors with optogenetic actuators (either direct targeting with *Tph2* promoter¹³⁰ or a combination of TPH2-Cre with a Cre-dependent vector) may be used in this species.

In any case, using blue light for activation of optogenetic constructs requires careful controls for the effects of temperature and blue light itself. For example, we recently reported that blue light induces activation-like signals in functional magnetic resonance imaging experiments probably due to the local heating.¹³¹ Control for the effects of blue light has become a particular issue since the recent demonstration of the vasomotor effects mediated by melanopsin in peripheral blood vessels.¹³² Development of more sensitive optogenetic tools that can be activated by application of low intensity light¹³³⁻¹³⁶ will help to overcome these concerns.

The techniques discussed in this section allow manipulations of specific neuronal populations in freely behaving animals with improved spatial and temporal precision. Optogenetics and DREADDs both involve the introduction of non-native proteins into neurons that thereby respond to defined stimuli (light or CNO) with altered excitability. For the analysis of temporal dynamics of specific circuits, optogenetics must be used, whereby an optical fiber needs to be implanted and manipulations can only affect the illuminated area in the brain. In contrast, by a simple systemic CNO administration all DREADDs distributed within large tissue volumes can be stimulated simultaneously. Likewise, the tet-Off system allows gene expression control in all tissues expressing the chosen promoter. In all cases, unknown side effects of chemical agent administration or blue light have to be considered.^{101, 102, 131, 132, 137-139}

Summary

Serotonergic neurons in the raphe nuclei give rise to a complex and extensive network of axonal projections throughout the whole brain. A major challenge in the analysis of these circuits is to understand how the serotonergic networks are linked to the numerous

functions of this neurotransmitter. Several new methodologies to manipulate subpopulations of serotonergic neurons and to control 5-HT neuron activity have been developed during recent years, including the generation of different serotonergic-neuron-specific Cre lines, the invention of a dual recombination strategy, effective tools for temporal control of gene expression, DREADDs, and optogenetics. The nature of the experimental question dictates which option should be chosen as each has different merits and limitations. Importantly, since none of the described systems is totally free of nonspecific effects. For the most accurate and informative interpretation of results, adequate controls should be incorporated into experimental designs. Nonetheless, these new tools and methods, alone and in combination, enable powerful new routes to investigate the serotonin system.

Acknowledgements: This work was supported by fellowship from the European Molecular Biology Organization (EMBO) (ASTF 72-2014) and in part by the grant from the Russian Science Foundation № 14-50-00069 to NA, and from the Federation of European Neuroscience (FENS) to VM (NENS, 2013).

Abbreviations

5-HT - 5-hydroxytryptamine

AAV - Adeno associated viral vector

BAC - Bacterial artificial chromosome

BLA - Basolateral amygdala

CAV2 - canine adenovirus serotype 2

ChR2 - Channelrhodopsin 2

CNO - Clozapine-N-oxide

CNS - Central nervous system

CR - Caudal raphe

Di - Synthetic Gi/o-protein coupled receptor (DREADD)

Dox - Doxycycline

DR - Dorsal raphe

DREADD - Designer Receptors Exclusively Activated by Designer Drugs

En1 - Engrailed 1

Flp – Flippase

GOI - Gene of interest

IHC - Immunohistochemistry

LacZ - Gene coding for β -galactosidase

Lmx1b - LIM homeobox transcription factor 1

NTS - Nucleus tractus solitarii

MnR - Median raphe

ObRb - Leptin receptor b

LepRb - Leptin receptor b

Pet1 - PC12 ETS domain-containing transcription factor 1

Ptet - Tet-promoter

r - Rhombomere

RM - Raphe magnus

RO - Raphe obscurus

SERT - Serotonin transporter

SSRI - Serotonin reuptake inhibitor

Tet - Tetracyclin

TMX - Tamoxifen

Tox - Tetanus toxin light chain

TPH2 - Tryptophan hydroxylase 2

tTA - tetracycline transactivator

VMAT - Vesicular monoamine transporter

β -Gal - β -galactosidase

DT - Diphtheria toxin

TVA protein - Cognate receptor

Figure legends

Figure 1. Cre-mediated recombination in the TPH2-iCreERT2 mouse. **A.** LacZ expression in the raphe nuclei of the TPH2-iCreERT2 x R26R double transgenic mouse. DR – dorsal raphe nucleus, MnR – median raphe nuclei, CR – caudal raphe nuclei. **B.** EYFP expression (immunohistochemistry with anti-GFP antibody) in the dorsal raphe nuclei of the TPH2-iCreERT2 x ROSA26loxP-stop-EYFP double transgenic mouse. **C.** Expression of tdTomato in the raphe of TPH2-iCreERT2 x Rosa26loxP-STOP-tdTomato reporter mice. Arrowhead indicates neuronal cell bodies, arrow -indicates neuronal processes. **D.** EYFP expression (immunohistochemistry with anti-GFP antibody) in the dorsal raphe nuclei of the TPH2-iCreERT2 mouse injected with AAV virus (EF1a-DIO-CheTA-EYFP).

In all experiments Cre expression was induced by 3 consecutive TMX injections (120 mg/kg for A, B and C, and 100 mg/kg for D) on days 1, 3, and 5. Mice were sacrificed on day 12-15.

Figure 2. TPH2-ChR2-EYFP mouse as a model for the study of serotonergic circuitry. **A.** Specificity of EYFP expression controlled by *Tph2* promoter: immunohistochemical analysis with anti-5-HT antibodies in dorsal raphe nuclei in TPH2-ChR2 mouse (10x (left panel) and 40x (right panel) magnification. Neuronal activation in lamina I/II of the dorsal horn of the spinal cord was investigated through analysis of c-Fos expression (as previously described in ¹¹²) following application of a series of noxious pinch stimuli (pneumatic pincher: 2.5 N x 3) of the left hindpaw in control and TPH2-ChR2-EYFP mice during optogenetic stimulation (10 msec ON, 10 msec OFF, 20 sec, 20 mV) in the dorsolateral dorsal raphe nucleus (coordinates from lambda: 0.3 mm ML, -1 mm AP, -3.4 mm DV). **B.** In both TPH2-ChR2 and control mice, higher numbers of c-Fos positive neurons were observed ipsilateral to the pinch stimulus compared to the contralateral side. No significant difference was observed between control and stimulated animals, however a large variance in the number of c-Fos positive neurons was observed in both groups of animals. n=8 per group. **p<0.01 compared to contralateral side of the animals of the same genotype, Wilcoxon matched-pairs signed rank test. **C.** Transverse spinal cord section with lamina boundaries indicated. Black arrow indicates an incision made prior to sectioning to mark the contralateral side of the cord. Boxed areas indicate regions displayed at higher magnification in (D). **D.** Representative images of spinal cord sections from control and TPH2-ChR2-EYFP animals that displayed high or low counts of c-Fos positive dorsal horn neurons.

References

- [1] Walther, D. J., and Bader, M. (2003) A unique central tryptophan hydroxylase isoform, *Biochem Pharmacol* 66, 1673-1680.
- [2] Zill, P., Büttner, A., Eisenmenger, W., Möller, H.-J., Ackenheil, M., and Bondy, B. (2005) Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: A post-mortem study, *Journal of Psychiatric Research* 41, 168-173.
- [3] Sakowski, S. A., Geddes, T. J., Thomas, D. M., Levi, E., Hatfield, J. S., and Kuhn, D. M. (2006) Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies, *Brain Res* 1085, 11-18.
- [4] Kriegebaum, C. (2009) Spatio-temporal expression patterns of the serotonin synthesis enzymes TPH1 and TPH2 and effects of acute stress, PhD dissertation, In *Department of Psychiatry, Psychosomatics and Psychotherapy*, Julius-Maximilians-University, Wuerzburg
- [5] McKinney, J., Knappskog, P. M., and Haavik, J. (2005) Different properties of the central and peripheral forms of human tryptophan hydroxylase, *J Neurochem* 92, 311-320.
- [6] Walther, D. J., Peter, J. U., Bashammakh, S., Hortnagl, H., Voits, M., Fink, H., and Bader, M. (2003) Synthesis of serotonin by a second tryptophan hydroxylase isoform, *Science* 299, 76.
- [7] Henry, J. P., Sagne, C., Bedet, C., and Gasnier, B. (1998) The vesicular monoamine transporter: from chromaffin granule to brain, *Neurochemistry international* 32, 227-246.
- [8] Hoyer, D., Clarke, D. E., Fozard, J. R., Hartig, P. R., Martin, G. R., Mylecharane, E. J., Saxena, P. R., and Humphrey, P. P. (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin), *Pharmacological Reviews* 46, 157-203.
- [9] Filip, M., and Bader, M. (2009) Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system, *Pharmacol Rep* 61, 761-777.
- [10] Blier, P., Pineyro, G., el Mansari, M., Bergeron, R., and de Montigny, C. (1998) Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission, *Ann N Y Acad Sci* 861, 204-216.
- [11] Pineyro, G., and Blier, P. (1999) Autoregulation of serotonin neurons: role in antidepressant drug action, *Pharmacol Rev* 51, 533-591.
- [12] Inazu, M., Takeda, H., Ikoshi, H., Sugisawa, M., Uchida, Y., and Matsumiya, T. (2001) Pharmacological characterization and visualization of the glial serotonin transporter, *Neurochemistry international* 39, 39-49.
- [13] Gaspar, P., Cases, O., and Maroteaux, L. (2003) The developmental role of serotonin: news from mouse molecular genetics, *Nat Rev Neurosci* 4, 1002-1012.
- [14] Blakely, R. D. (2001) Physiological genomics of antidepressant targets: keeping the periphery in mind, *J Neurosci* 21, 8319-8323.
- [15] Martel, F. (2006) Recent advances on the importance of the serotonin transporter SERT in the rat intestine, *Pharmacological research : the official journal of the Italian Pharmacological Society* 54, 73-76.
- [16] Wylie, C. J., Hendricks, T. J., Zhang, B., Wang, L., Lu, P., Leahy, P., Fox, S., Maeno, H., and Deneris, E. S. (2010) Distinct transcriptomes define rostral and caudal serotonin neurons, *J Neurosci* 30, 670-684.

- [17] Beck, S. G., Pan, Y. Z., Akanwa, A. C., and Kirby, L. G. (2004) Median and dorsal raphe neurons are not electrophysiologically identical, *J Neurophysiol* 91, 994-1005.
- [18] Kocsis, B., Varga, V., Dahan, L., and Sik, A. (2006) Serotonergic neuron diversity: identification of raphe neurons with discharges time-locked to the hippocampal theta rhythm, *Proceedings of the National Academy of Sciences of the United States of America* 103, 1059-1064.
- [19] Kiyasova, V., and Gaspar, P. (2011) Development of raphe serotonin neurons from specification to guidance, *Eur J Neurosci* 34, 1553-1562.
- [20] Kiyasova, V., Bonnavion, P., Scotto-Lomassese, S., Fabre, V., Sahly, I., Tronche, F., Deneris, E., Gaspar, P., and Fernandez, S. P. (2013) A subpopulation of serotonergic neurons that do not express the 5-HT_{1A} autoreceptor, *ACS chemical neuroscience* 4, 89-95.
- [21] Muzerelle, A., Scotto-Lomassese, S., Bernard, J. F., Soiza-Reilly, M., and Gaspar, P. (2014) Conditional anterograde tracing reveals distinct targeting of individual serotonin cell groups (B5-B9) to the forebrain and brainstem, *Brain structure & function*.
- [22] Zhao, Z. Q., Scott, M., Chiechio, S., Wang, J. S., Renner, K. J., Gereau, R. W. t., Johnson, R. L., Deneris, E. S., and Chen, Z. F. (2006) Lmx1b is required for maintenance of central serotonergic neurons and mice lacking central serotonergic system exhibit normal locomotor activity, *J Neurosci* 26, 12781-12788.
- [23] Hendricks, T., Francis, N., Fyodorov, D., and Deneris, E. S. (1999) The ETS domain factor Pet-1 is an early and precise marker of central serotonin neurons and interacts with a conserved element in serotonergic genes, *J Neurosci* 19, 10348-10356.
- [24] Ding, Y. Q., Marklund, U., Yuan, W., Yin, J., Wegman, L., Ericson, J., Deneris, E., Johnson, R. L., and Chen, Z. F. (2003) Lmx1b is essential for the development of serotonergic neurons, *Nat Neurosci* 6, 933-938.
- [25] Cheng, L., Chen, C. L., Luo, P., Tan, M., Qiu, M., Johnson, R., and Ma, Q. (2003) Lmx1b, Pet-1, and Nkx2.2 coordinately specify serotonergic neurotransmitter phenotype, *J Neurosci* 23, 9961-9967.
- [26] Pelosi, B., Migliarini, S., Pacini, G., Pratelli, M., and Pasqualetti, M. (2014) Generation of Pet1210-Cre transgenic mouse line reveals non-serotonergic expression domains of Pet1 both in CNS and periphery, *PLoS One* 9, e104318.
- [27] Deneris, E. S. (2011) Molecular genetics of mouse serotonin neurons across the lifespan, *Neuroscience* 197, 17-27.
- [28] Scott, M. M., Wylie, C. J., Lerch, J. K., Murphy, R., Lobur, K., Herlitze, S., Jiang, W., Conlon, R. A., Strowbridge, B. W., and Deneris, E. S. (2005) A genetic approach to access serotonin neurons for in vivo and in vitro studies, *Proceedings of the National Academy of Sciences of the United States of America* 102, 16472-16477.
- [29] Migliarini, S., Pacini, G., Pelosi, B., Lunardi, G., and Pasqualetti, M. (2013) Lack of brain serotonin affects postnatal development and serotonergic neuronal circuitry formation, *Mol Psychiatry* 18, 1106-1118.
- [30] Yadav, V. K., Oury, F., Suda, N., Liu, Z. W., Gao, X. B., Confavreux, C., Klemenhagen, K. C., Tanaka, K. F., Gingrich, J. A., Guo, X. E., Tecott, L. H., Mann, J. J., Hen, R., Horvath, T. L., and Karsenty, G. (2009) A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure, *Cell* 138, 976-989.
- [31] Alenina, N., Kikic, D., Todiras, M., Mosienko, V., Qadri, F., Plehm, R., Boye, P., Vilianovitch, L., Sohr, R., Tenner, K., Hortnagl, H., and Bader, M. (2009) Growth retardation and altered autonomic control in mice lacking brain serotonin, *Proceedings of the National Academy of Sciences of the*

- [32] Beaulieu, J. M., Zhang, X., Rodriguiz, R. M., Sotnikova, T. D., Cools, M. J., Wetsel, W. C., Gainetdinov, R. R., and Caron, M. G. (2008) Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency, *Proceedings of the National Academy of Sciences of the United States of America* 105, 1333-1338.
- [33] Bert, B., Dere, E., Wilhelmi, N., Kusserow, H., Theuring, F., Huston, J. P., and Fink, H. (2005) Transient overexpression of the 5-HT_{1A} receptor impairs water-maze but not hole-board performance, *Neurobiol Learn Mem* 84, 57-68.
- [34] Fukui, M., Rodriguiz, R. M., Zhou, J., Jiang, S. X., Phillips, L. E., Caron, M. G., and Wetsel, W. C. (2007) Vmat2 heterozygous mutant mice display a depressive-like phenotype, *J Neurosci* 27, 10520-10529.
- [35] Hendricks, T. J., Fyodorov, D. V., Wegman, L. J., Lelutiu, N. B., Pehek, E. A., Yamamoto, B., Silver, J., Weeber, E. J., Sweatt, J. D., and Deneris, E. S. (2003) Pet-1 ETS gene plays a critical role in 5-HT neuron development and is required for normal anxiety-like and aggressive behavior, *Neuron* 37, 233-247.
- [36] Holmes, A., Murphy, D. L., and Crawley, J. N. (2003) Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression, *Biol Psychiatry* 54, 953-959.
- [37] Pringle, A., Jennings, K. A., Line, S., Bannerman, D. M., Higgs, S., and Sharp, T. (2008) Mice overexpressing the 5-hydroxytryptamine transporter show no alterations in feeding behaviour and increased non-feeding responses to fenfluramine, *Psychopharmacology (Berl)* 200, 291-300.
- [38] Ramboz, S., Oosting, R., Amara, D. A., Kung, H. F., Blier, P., Mendelsohn, M., Mann, J. J., Brunner, D., and Hen, R. (1998) Serotonin receptor 1A knockout: An animal model of anxiety-related disorder, *Proceedings of the National Academy of Sciences of the United States of America* 95, 14476-14481.
- [39] Fernandez, S. P., and Gaspar, P. (2012) Investigating anxiety and depressive-like phenotypes in genetic mouse models of serotonin depletion, *Neuropharmacology* 62, 144-154.
- [40] Lesch, K. P., Araragi, N., Waider, J., van den Hove, D., and Gutknecht, L. (2012) Targeting brain serotonin synthesis: insights into neurodevelopmental disorders with long-term outcomes related to negative emotionality, aggression and antisocial behaviour, *Philosophical transactions of the Royal Society of London. Series B, Biological sciences* 367, 2426-2443.
- [41] Mosienko, V., Beis, D., Pasqualetti, M., Waider, J., Matthes, S., Qadri, F., Bader, M., and Alenina, N. (2015) Life without brain serotonin: reevaluation of serotonin function with mice deficient in brain serotonin synthesis, *Behav Brain Res* 277, 78-88.
- [42] Trowbridge, S., Narboux-Neme, N., and Gaspar, P. (2011) Genetic models of serotonin (5-HT) depletion: what do they tell us about the developmental role of 5-HT?, *Anat Rec (Hoboken)* 294, 1615-1623.
- [43] Kuhn, R., and Torres, R. M. (2002) Cre/loxP recombination system and gene targeting, *Methods Mol Biol* 180, 175-204.
- [44] Schwenk, F., Baron, U., and Rajewsky, K. (1995) A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells, *Nucleic Acids Research* 23, 5080-5081.
- [45] Shizuya, H., Birren, B., Kim, U. J., Mancino, V., Slepak, T., Tachiiri, Y., and Simon, M. (1992) Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an

F-factor-based vector, *Proceedings of the National Academy of Sciences of the United States of America* 89, 8794-8797.

- [46] Ioannou, P. A., Amemiya, C. T., Garnes, J., Kroisel, P. M., Shizuya, H., Chen, C., Batzer, M. A., and de Jong, P. J. (1994) A new bacteriophage P1-derived vector for the propagation of large human DNA fragments, *Nat Genet* 6, 84-89.
- [47] Stone, N. E., Fan, J. B., Willour, V., Pennacchio, L. A., Warrington, J. A., Hu, A., de la Chapelle, A., Lehesjoki, A. E., Cox, D. R., and Myers, R. M. (1996) Construction of a 750-kb bacterial clone contig and restriction map in the region of human chromosome 21 containing the progressive myoclonus epilepsy gene, *Genome Res* 6, 218-225.
- [48] Copeland, N. G., Jenkins, N. A., and Court, D. L. (2001) Recombineering: a powerful new tool for mouse functional genomics, *Nat Rev Genet* 2, 769-779.
- [49] Gong, S., Doughty, M., Harbaugh, C. R., Cummins, A., Hatten, M. E., Heintz, N., and Gerfen, C. R. (2007) Targeting Cre recombinase to specific neuron populations with bacterial artificial chromosome constructs, *J Neurosci* 27, 9817-9823.
- [50] Zhuang, X., Masson, J., Gingrich, J. A., Rayport, S., and Hen, R. (2005) Targeted gene expression in dopamine and serotonin neurons of the mouse brain, *J Neurosci Methods* 143, 27-32.
- [51] Mosienko, V., Matthes, S., Hirth, N., Beis, D., Flinders, M., Bader, M., Hansson, A. C., and Alenina, N. (2014) Adaptive changes in serotonin metabolism preserve normal behavior in mice with reduced TPH2 activity, *Neuropharmacology* 85, 73-80.
- [52] Soriano, P. (1999) Generalized lacZ expression with the ROSA26 Cre reporter strain, *Nat Genet* 21, 70-71.
- [53] Srinivas, S., Watanabe, T., Lin, C. S., William, C. M., Tanabe, Y., Jessell, T. M., and Costantini, F. (2001) Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus, *BMC Dev Biol* 1, 4.
- [54] Hayashi, S., and McMahon, A. P. (2002) Efficient Recombination in Diverse Tissues by a Tamoxifen-Inducible Form of Cre: A Tool for Temporally Regulated Gene Activation/Inactivation in the Mouse, *Developmental Biology* 244, 305-318.
- [55] Garcia-Otin, A. L., and Guillou, F. (2006) Mammalian genome targeting using site-specific recombinases, *Frontiers in bioscience : a journal and virtual library* 11, 1108-1136.
- [56] Bruchas, Michael R., Schindler, Abigail G., Shankar, H., Messinger, Daniel I., Miyatake, M., Land, Benjamin B., Lemos, Julia C., Hagan, C. E., Neumaier, John F., Quintana, A., Palmiter, Richard D., and Chavkin, C. (2011) Selective p38 α MAPK Deletion in Serotonergic Neurons Produces Stress Resilience in Models of Depression and Addiction, *Neuron* 71, 498-511.
- [57] Pavone, L. M., Spina, A., Rea, S., Santoro, D., Mastellone, V., Lombardi, P., and Avallone, L. (2009) Serotonin transporter gene deficiency is associated with sudden death of newborn mice through activation of TGF- β 1 signalling, *Journal of Molecular and Cellular Cardiology* 47, 691-697.
- [58] Narboux-Neme, N., Pavone, L. M., Avallone, L., Zhuang, X., and Gaspar, P. (2008) Serotonin transporter transgenic (SERTcre) mouse line reveals developmental targets of serotonin specific reuptake inhibitors (SSRIs), *Neuropharmacology* 55, 994-1005.
- [59] Lam, D. D., Leininger, G. M., Louis, G. W., Garfield, A. S., Marston, O. J., Leshan, R. L., Scheller, E. L., Christensen, L., Donato, J., Jr., Xia, J., Evans, M. L., Elias, C., Dalley, J. W., Burdakov, D. I., Myers, M. G., Jr., and Heisler, L. K. (2011) Leptin does not directly affect CNS serotonin neurons to influence appetite, *Cell metabolism* 13, 584-591.

- [60] Spina, A., Rea, S., De Pasquale, V., Mastellone, V., Avallone, L., and Pavone, L. M. (2011) Fate map of serotonin transporter-expressing cells in developing mouse thyroid, *Anat Rec (Hoboken)* 294, 384-390.
- [61] Narboux-Neme, N., Sagne, C., Doly, S., Diaz, S. L., Martin, C. B., Angenard, G., Martres, M. P., Giros, B., Hamon, M., Lanfumey, L., Gaspar, P., and Mongeau, R. (2011) Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences, *Neuropsychopharmacology* 36, 2538-2550.
- [62] Lebrand, C., Cases, O., Wehrle, R., Blakely, R. D., Edwards, R. H., and Gaspar, P. (1998) Transient developmental expression of monoamine transporters in the rodent forebrain, *J Comp Neurol* 401, 506-524.
- [63] Zhang, Z. W., Peterson, M., and Liu, H. (2013) Essential role of postsynaptic NMDA receptors in developmental refinement of excitatory synapses, *Proceedings of the National Academy of Sciences of the United States of America* 110, 1095-1100.
- [64] Koch, S. M., Dela Cruz, C. G., Hnasko, T. S., Edwards, R. H., Huberman, A. D., and Ullian, E. M. (2011) Pathway-specific genetic attenuation of glutamate release alters select features of competition-based visual circuit refinement, *Neuron* 71, 235-242.
- [65] Zhang, W., Peterson, M., Beyer, B., Frankel, W. N., and Zhang, Z. W. (2014) Loss of MeCP2 from forebrain excitatory neurons leads to cortical hyperexcitation and seizures, *J Neurosci* 34, 2754-2763.
- [66] Jensen, P., Farago, A. F., Awatramani, R. B., Scott, M. M., Deneris, E. S., and Dymecki, S. M. (2008) Redefining the serotonergic system by genetic lineage, *Nat Neurosci* 11, 417-419.
- [67] Dai, J. X., Han, H. L., Tian, M., Cao, J., Xiu, J. B., Song, N. N., Huang, Y., Xu, T. L., Ding, Y. Q., and Xu, L. (2008) Enhanced contextual fear memory in central serotonin-deficient mice, *Proceedings of the National Academy of Sciences of the United States of America* 105, 11981-11986.
- [68] Song, N. N., Xiu, J. B., Huang, Y., Chen, J. Y., Zhang, L., Gutknecht, L., Lesch, K. P., Li, H., and Ding, Y. Q. (2011) Adult raphe-specific deletion of *Lmx1b* leads to central serotonin deficiency, *PLoS One* 6, e15998.
- [69] Wong, A. A., and Brown, R. E. (2006) Visual detection, pattern discrimination and visual acuity in 14 strains of mice, *Genes Brain Behav* 5, 389-403.
- [70] Weber, T., Bohm, G., Hermann, E., Schutz, G., Schonig, K., and Bartsch, D. (2009) Inducible gene manipulations in serotonergic neurons, *Front Mol Neurosci* 2, 24.
- [71] Weber, T., Schonig, K., Tews, B., and Bartsch, D. (2011) Inducible gene manipulations in brain serotonergic neurons of transgenic rats, *PLoS One* 6, e28283.
- [72] Yadav, V. K., Oury, F., Tanaka, K., Thomas, T., Wang, Y., Cremers, S., Hen, R., Krust, A., Chambon, P., and Karsenty, G. (2011) Leptin-dependent serotonin control of appetite: temporal specificity, transcriptional regulation, and therapeutic implications, *The Journal of Experimental Medicine* 208, 41-52.
- [73] Feil, R., Wagner, J., Metzger, D., and Chambon, P. (1997) Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains, *Biochem Biophys Res Commun* 237, 752-757.
- [74] Shimshek, D. R., Kim, J., Hubner, M. R., Spergel, D. J., Buchholz, F., Casanova, E., Stewart, A. F., Seeburg, P. H., and Sprengel, R. (2002) Codon-improved Cre recombinase (iCre) expression in the mouse, *Genesis* 32, 19-26.
- [75] Narboux-Neme, N., Angenard, G., Mosienko, V., Klempin, F., Pitychoutis, P. M., Deneris, E., Bader,

M., Giros, B., Alenina, N., and Gaspar, P. (2013) Postnatal growth defects in mice with constitutive depletion of central serotonin, *ACS Chem Neurosci* 4, 171-181.

- [76] Brust, R. D., Corcoran, A. E., Richerson, G. B., Nattie, E., and Dymecki, S. M. (2014) Functional and developmental identification of a molecular subtype of brain serotonergic neuron specialized to regulate breathing dynamics, *Cell reports* 9, 2152-2165.
- [77] Kim, J. C., Cook, M. N., Carey, M. R., Shen, C., Regehr, W. G., and Dymecki, S. M. (2009) Linking genetically defined neurons to behavior through a broadly applicable silencing allele, *Neuron* 63, 305-315.
- [78] Thévenot, E., Côté, F., Colin, P., He, Y., Leblois, H., Perricaudet, M., Mallet, J., and Vojdani, G. (2003) Targeting conditional gene modification into the serotonin neurons of the dorsal raphe nucleus by viral delivery of the Cre recombinase, *Molecular and Cellular Neuroscience* 24, 139-147.
- [79] Zhu, Y., Romero, M. I., Ghosh, P., Ye, Z., Charnay, P., Rushing, E. J., Marth, J. D., and Parada, L. F. (2001) Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain, *Genes Dev* 15, 859-876.
- [80] Araki, K., Araki, M., Miyazaki, J., and Vassalli, P. (1995) Site-specific recombination of a transgene in fertilized eggs by transient expression of Cre recombinase, *Proceedings of the National Academy of Sciences of the United States of America* 92, 160-164.
- [81] Benzekhroufa, K., Liu, B. H., Teschemacher, A. G., and Kasparov, S. (2009) Targeting central serotonergic neurons with lentiviral vectors based on a transcriptional amplification strategy, *Gene therapy* 16, 681-688.
- [82] Depuy, S. D., Kanbar, R., Coates, M. B., Stornetta, R. L., and Guyenet, P. G. (2011) Control of breathing by raphe obscurus serotonergic neurons in mice, *J Neurosci* 31, 1981-1990.
- [83] Ogawa, S. K., Cohen, J. Y., Hwang, D., Uchida, N., and Watabe-Uchida, M. (2014) Organization of monosynaptic inputs to the serotonin and dopamine neuromodulatory systems, *Cell reports* 8, 1105-1118.
- [84] Pollak Dorocic, I., Furth, D., Xuan, Y., Johansson, Y., Pozzi, L., Silberberg, G., Carlen, M., and Meletis, K. (2014) A whole-brain atlas of inputs to serotonergic neurons of the dorsal and median raphe nuclei, *Neuron* 83, 663-678.
- [85] Rothmel, M., Brunert, D., Zabawa, C., Díaz-Quesada, M., and Wachowiak, M. (2013) Transgene Expression in Target-Defined Neuron Populations Mediated by Retrograde Infection with Adeno-Associated Viral Vectors, *The Journal of Neuroscience* 33, 15195-15206.
- [86] Sparta, Dennis R., and Stuber, Garret D. (2014) Cartography of Serotonergic Circuits, *Neuron* 83, 513-515.
- [87] Suzuki, Y., Kiyokage, E., Sohn, J., Hioki, H., and Toida, K. (2015) Structural basis for serotonergic regulation of neural circuits in the mouse olfactory bulb, *J Comp Neurol* 523, 262-280.
- [88] Watabe-Uchida, M., Zhu, L., Ogawa, S. K., Vamanrao, A., and Uchida, N. (2012) Whole-brain mapping of direct inputs to midbrain dopamine neurons, *Neuron* 74, 858-873.
- [89] Weissbourd, B., Ren, J., DeLoach, K. E., Guenther, C. J., Miyamichi, K., and Luo, L. (2014) Presynaptic partners of dorsal raphe serotonergic and GABAergic neurons, *Neuron* 83, 645-662.
- [90] Wu, Q., Clark, M. S., and Palmiter, R. D. (2012) Deciphering a neuronal circuit that mediates appetite, *Nature* 483, 594-597.
- [91] Furuta, T., Tomioka, R., Taki, K., Nakamura, K., Tamamaki, N., and Kaneko, T. (2001) In vivo

transduction of central neurons using recombinant Sindbis virus: Golgi-like labeling of dendrites and axons with membrane-targeted fluorescent proteins, *J Histochem Cytochem* 49, 1497-1508.

- [92] Ugolini, G. (2011) Rabies virus as a transneuronal tracer of neuronal connections, *Adv Virus Res* 79, 165-202.
- [93] Barkats, M., Bilang-Bleuel, A., Buc-Caron, M. H., Castel-Barthe, M. N., Corti, O., Finiels, F., Horellou, P., Revah, F., Sabate, O., and Mallet, J. (1998) Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases, *Progress in neurobiology* 55, 333-341.
- [94] Bohn, M. C., Choi-Lundberg, D. L., Davidson, B. L., Leranthe, C., Kozlowski, D. A., Smith, J. C., O'Banion, M. K., and Redmond, D. E., Jr. (1999) Adenovirus-mediated transgene expression in nonhuman primate brain, *Human gene therapy* 10, 1175-1184.
- [95] Figueiredo, M., Lane, S., Tang, F., Liu, B. H., Hewinson, J., Marina, N., Kasymov, V., Souslova, E. A., Chudakov, D. M., Gourine, A. V., Teschemacher, A. G., and Kasparov, S. (2011) Optogenetic experimentation on astrocytes, *Experimental physiology* 96, 40-50.
- [96] Hermens, W. T., and Verhaagen, J. (1998) Viral vectors, tools for gene transfer in the nervous system, *Progress in neurobiology* 55, 399-432.
- [97] Thomas, C. E., Abordo-Adesida, E., Maleniak, T. C., Stone, D., Gerdes, C. A., and Lowenstein, P. R. (2001) Gene transfer into rat brain using adenoviral vectors, *Curr Protoc Neurosci Chapter 4*, Unit 4 24.
- [98] Petrosyan, H. A., Alessi, V., Singh, V., Hunanyan, A. S., Levine, J. M., and Arvanian, V. L. (2014) Transduction efficiency of neurons and glial cells by AAV-1, -5, -9, -rh10 and -hu11 serotypes in rat spinal cord following contusion injury, *Gene therapy* 21, 991-1000.
- [99] Ortinski, P. I., Dong, J., Mungenast, A., Yue, C., Takano, H., Watson, D. J., Haydon, P. G., and Coulter, D. A. (2010) Selective induction of astrocytic gliosis generates deficits in neuronal inhibition, *Nature neuroscience* 13, 584-591.
- [100] Gloss, B. (2011) Generation of an inducible Tph2 cre transgene MGI Direct Data Submission, *MGI Ref ID J:173677*.
- [101] Huh, W. J., Khurana, S. S., Geahlen, J. H., Kohli, K., Waller, R. A., and Mills, J. C. (2012) Tamoxifen induces rapid, reversible atrophy, and metaplasia in mouse stomach, *Gastroenterology* 142, 21-24.e27.
- [102] Higashi, A. Y., Ikawa, T., Muramatsu, M., Economides, A. N., Niwa, A., Okuda, T., Murphy, A. J., Rojas, J., Heike, T., Nakahata, T., Kawamoto, H., Kita, T., and Yanagita, M. (2009) Direct Hematological Toxicity and Illegitimate Chromosomal Recombination Caused by the Systemic Activation of CreERT2, *The Journal of Immunology* 182, 5633-5640.
- [103] Audero, E., Mlinar, B., Baccini, G., Skachokova, Z. K., Corradetti, R., and Gross, C. (2013) Suppression of serotonin neuron firing increases aggression in mice, *J Neurosci* 33, 8678-8688.
- [104] Kistner, A., Gossen, M., Zimmermann, F., Jerecic, J., Ullmer, C., Lubbert, H., and Bujard, H. (1996) Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice, *Proceedings of the National Academy of Sciences of the United States of America* 93, 10933-10938.
- [105] Gross, C., Zhuang, X., Stark, K., Ramboz, S., Oosting, R., Kirby, L., Santarelli, L., Beck, S., and Hen, R. (2002) Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult, *Nature* 416, 396-400.
- [106] Weber, T., Renzland, I., Baur, M., Monks, S., Herrmann, E., Huppert, V., Nurnberg, F., Schonig, K., and Bartsch, D. (2012) Tetracycline inducible gene manipulation in serotonergic neurons, *PLoS One*

- [107] Ferguson, S. M., Eskenazi, D., Ishikawa, M., Wanat, M. J., Phillips, P. E., Dong, Y., Roth, B. L., and Neumaier, J. F. (2011) Transient neuronal inhibition reveals opposing roles of indirect and direct pathways in sensitization, *Nat Neurosci* 14, 22-24.
- [108] Krashes, M. J., Koda, S., Ye, C., Rogan, S. C., Adams, A. C., Cusher, D. S., Maratos-Flier, E., Roth, B. L., and Lowell, B. B. (2011) Rapid, reversible activation of AgRP neurons drives feeding behavior in mice, *J Clin Invest* 121, 1424-1428.
- [109] Ray, R. S., Corcoran, A. E., Brust, R. D., Kim, J. C., Richerson, G. B., Nattie, E., and Dymecki, S. M. (2011) Impaired respiratory and body temperature control upon acute serotonergic neuron inhibition, *Science* 333, 637-642.
- [110] Armbruster, B. N., Li, X., Pausch, M. H., Herlitze, S., and Roth, B. L. (2007) Evolving the lock to fit the key to create a family of G protein-coupled receptors potentially activated by an inert ligand, *Proceedings of the National Academy of Sciences of the United States of America* 104, 5163-5168.
- [111] Loffler, S., Korber, J., Nubbemeyer, U., and Fehsel, K. (2012) Comment on "Impaired respiratory and body temperature control upon acute serotonergic neuron inhibition", *Science* 337, 646; author reply 646.
- [112] Pirmohamed, M., Williams, D., Madden, S., Templeton, E., and Park, B. K. (1995) Metabolism and bioactivation of clozapine by human liver in vitro, *The Journal of pharmacology and experimental therapeutics* 272, 984-990.
- [113] Takekawa, K., Kitamura, S., Sugihara, K., and Ohta, S. (2001) Non-enzymatic reduction of aliphatic tertiary amine N-oxides mediated by the haem moiety of cytochrome P450, *Xenobiotica; the fate of foreign compounds in biological systems* 31, 11-23.
- [114] Nawaratne, V., Leach, K., Suratman, N., Loiacono, R. E., Felder, C. C., Armbruster, B. N., Roth, B. L., Sexton, P. M., and Christopoulos, A. (2008) New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug), *Molecular pharmacology* 74, 1119-1131.
- [115] Kasparov, S., and Herlitze, S. (2013) Optogenetics at a crossroads?, *Exp Physiol* 98, 971-972.
- [116] Zhao, S., Ting, J. T., Atallah, H. E., Qiu, L., Tan, J., Gloss, B., Augustine, G. J., Deisseroth, K., Luo, M., Graybiel, A. M., and Feng, G. (2011) Cell type-specific channelrhodopsin-2 transgenic mice for optogenetic dissection of neural circuitry function, *Nature Methods* 8, 745-752.
- [117] Tenen, S. S. (1967) The effects of p-chlorophenylalanine, a serotonin depletor, on avoidance acquisition, pain sensitivity and related behavior in the rat, *Psychopharmacologia* 10, 204-219.
- [118] Hutson, P. H., Tricklebank, M. D., and Curzon, G. (1982) Enhancement of footshock-induced analgesia by spinal 5,7-dihydroxytryptamine lesions, *Brain Res* 237, 367-372.
- [119] Milne, R. J., and Gamble, G. D. (1990) Behavioural modification of bulbospinal serotonergic inhibition and morphine analgesia, *Brain Res* 521, 167-174.
- [120] Tjolsen, A., Berge, O. G., and Hole, K. (1991) Lesions of bulbo-spinal serotonergic or noradrenergic pathways reduce nociception as measured by the formalin test, *Acta Physiol Scand* 142, 229-236.
- [121] Trudeau, L. E. (2004) Glutamate co-transmission as an emerging concept in monoamine neuron function, *J Psychiatry Neurosci* 29, 296-310.
- [122] Gras, C., Herzog, E., Bellenchi, G. C., Bernard, V., Ravassard, P., Pohl, M., Gasnier, B., Giros, B., and El Mestikawy, S. (2002) A third vesicular glutamate transporter expressed by cholinergic and

serotonergic neurons, *J Neurosci* 22, 5442-5451.

- [123] Fardin, V., Oliveras, J. L., and Besson, J. M. (1984) A reinvestigation of the analgesic effects induced by stimulation of the periaqueductal gray matter in the rat. II. Differential characteristics of the analgesia induced by ventral and dorsal PAG stimulation, *Brain Res* 306, 125-139.
- [124] Ito, H., Yanase, M., Yamashita, A., Kitabatake, C., Hamada, A., Suhara, Y., Narita, M., Ikegami, D., Sakai, H., Yamazaki, M., and Narita, M. (2013) Analysis of sleep disorders under pain using an optogenetic tool: possible involvement of the activation of dorsal raphe nucleus-serotonergic neurons, *Molecular Brain* 6, 59-59.
- [125] Hunt, S. P., Pini, A., and Evan, G. (1987) Induction of c-fos-like protein in spinal cord neurons following sensory stimulation, *Nature* 328, 632-634.
- [126] Koutsikou, S., Parry, D. M., MacMillan, F. M., and Lumb, B. M. (2007) Laminar organization of spinal dorsal horn neurones activated by C- vs. A-heat nociceptors and their descending control from the periaqueductal grey in the rat, *Eur J Neurosci* 26, 943-952.
- [127] Dugue, G. P., Lorincz, M. L., Lottem, E., Audero, E., Matias, S., Correia, P. A., Lena, C., and Mainen, Z. F. (2014) Optogenetic recruitment of dorsal raphe serotonergic neurons acutely decreases mechanosensory responsivity in behaving mice, *PLoS One* 9, e105941.
- [128] Johansson, R. S., Vallbo, A. B., and Westling, G. (1980) Thresholds of mechanosensitive afferents in the human hand as measured with von Frey hairs, *Brain Res* 184, 343-351.
- [129] Madisen, L., Mao, T., Koch, H., Zhuo, J. M., Berenyi, A., Fujisawa, S., Hsu, Y. W., Garcia, A. J., 3rd, Gu, X., Zanella, S., Kidney, J., Gu, H., Mao, Y., Hooks, B. M., Boyden, E. S., Buzsaki, G., Ramirez, J. M., Jones, A. R., Svoboda, K., Han, X., Turner, E. E., and Zeng, H. (2012) A toolbox of Cre-dependent optogenetic transgenic mice for light-induced activation and silencing, *Nat Neurosci* 15, 793-802.
- [130] Benzekhroufa, K., Liu, B., Tang, F., Teschemacher, A. G., and Kasparov, S. (2009) Adenoviral vectors for highly selective gene expression in central serotonergic neurons reveal quantal characteristics of serotonin release in the rat brain, *BMC Biotechnol* 9, 23.
- [131] Christie, I. N., Wells, J. A., Southern, P., Marina, N., Kasparov, S., Gourine, A. V., and Lythgoe, M. F. (2013) fMRI response to blue light delivery in the naive brain: implications for combined optogenetic fMRI studies, *Neuroimage* 66, 634-641.
- [132] Sikka, G., Hussmann, G. P., Pandey, D., Cao, S., Hori, D., Park, J. T., Stepan, J., Kim, J. H., Barodka, V., Myers, A. C., Santhanam, L., Nyhan, D., Halushka, M. K., Koehler, R. C., Snyder, S. H., Shimoda, L. A., and Berkowitz, D. E. (2014) Melanopsin mediates light-dependent relaxation in blood vessels, *Proceedings of the National Academy of Sciences of the United States of America* 111, 17977-17982.
- [133] Berndt, A., Lee, S. Y., Ramakrishnan, C., and Deisseroth, K. (2014) Structure-guided transformation of channelrhodopsin into a light-activated chloride channel, *Science* 344, 420-424.
- [134] Berndt, A., Yizhar, O., Gunaydin, L. A., Hegemann, P., and Deisseroth, K. (2009) Bi-stable neural state switches, *Nat Neurosci* 12, 229-234.
- [135] Chuong, A. S., Miri, M. L., Busskamp, V., Matthews, G. A., Acker, L. C., Sorensen, A. T., Young, A., Klapoetke, N. C., Henninger, M. A., Kodandaramaiah, S. B., Ogawa, M., Ramanlal, S. B., Bandler, R. C., Allen, B. D., Forest, C. R., Chow, B. Y., Han, X., Lin, Y., Tye, K. M., Roska, B., Cardin, J. A., and Boyden, E. S. (2014) Noninvasive optical inhibition with a red-shifted microbial rhodopsin, *Nat Neurosci* 17, 1123-1129.
- [136] Lin, J. Y., Knutsen, P. M., Muller, A., Kleinfeld, D., and Tsien, R. Y. (2013) ReaChR: a red-shifted

variant of channelrhodopsin enables deep transcranial optogenetic excitation, *Nat Neurosci* 16, 1499-1508.

- [137] Aston-Jones, G., and Deisseroth, K. (2013) Recent advances in optogenetics and pharmacogenetics, *Brain Res* 1511, 1-5.
- [138] Rogan, S. C., and Roth, B. L. (2011) Remote control of neuronal signaling, *Pharmacol Rev* 63, 291-315.
- [139] Schmidt-Supprian, M., and Rajewsky, K. (2007) Vagaries of conditional gene targeting, *Nat Immunol* 8, 665-668.